ANDAORALTABLET
Approved
Feb 2000
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TRIHEXYPHENIDYL HYDROCHLORIDE (trihexyphenidyl hydrochloride) by Hikma is clinical pharmacology trihexyphenidyl exerts a direct inhibitory effect upon the parasympathetic nervous system. First approved in 2000.
Drug data last refreshed 18h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Trihexyphenidyl exerts a direct inhibitory effect upon the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly upon the muscle tissue itself and indirectly through an inhibitory effect upon the parasympathetic nervous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Hikma
Worked on TRIHEXYPHENIDYL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.